Promising Early Results in NSCLC Trial with Deltacel-01 from Kiromic BioPharma

Kiromic BioPharma, Inc., a biopharmaceutical firm listed on the OTCQB as KRBP, has announced promising initial findings from its Phase 1 clinical study of Deltacel™ in treating advanced non-small cell lung cancer (NSCLC). The first patient to participate in the Deltacel-01 trial has shown signs of disease stabilization after six weeks of therapy, which has been consistently well-tolerated, aligning with the safety profile established earlier in January.
The patient, enrolled at the Beverly Hills Cancer Center (BHCC), began treatment following a diagnosis of rapidly progressing disease. A subsequent CT scan indicated a halt in disease progression, suggesting a potential progression-free survival period of 1.5 months. The company anticipates providing further updates as additional data is gathered and more patients join the clinical study.
Kiromic's CEO, Pietro Bersani, expressed optimism regarding the early efficacy results, highlighting the significance of these findings for a cancer type that sees over 2 million new cases annually worldwide. He emphasized the company's commitment to enhancing patient outcomes and to the thorough evaluation of Deltacel's potential in NSCLC treatment.
Dr. Afshin Eli Gabayan, the Principal Investigator at BHCC, also expressed optimism for the treatment's prospects and the ongoing collaboration with Kiromic to expand the study's participant base.
The Deltacel-01 trial is an open-label Phase 1 study designed to assess the safety and tolerability of Gamma Delta T Cell Infusions combined with low-dose radiotherapy in patients with stage 4 NSCLC. The primary goal is safety evaluation, with secondary objectives including response rates and survival metrics.
Deltacel (KB-GDT-01) is an experimental therapy derived from gamma delta T-cells, targeting solid tumors with a focus on NSCLC, which constitutes the majority of lung cancer cases. Preclinical studies have shown a favorable safety and efficacy profile when Deltacel is used in conjunction with low-dose radiation.
Kiromic BioPharma is a clinical-stage company that leverages its proprietary DIAMOND® AI 2.0 technology to develop cell therapies, particularly for immuno-oncology applications. The company is advancing a multi-indication platform based on the natural anti-tumor properties of Gamma Delta T-cells, with the DIAMOND® AI system designed to expedite the drug development process significantly.
The Beverly Hills Cancer Center is recognized for offering state-of-the-art cancer treatments and conducting leading clinical trials and research, attracting patients from around the world. The center's multidisciplinary team of medical experts provides comprehensive patient care and is actively involved in clinical research initiatives.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!